Literature DB >> 26157003

Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release.

Sang-Hun Lee1, Marco Ledri2, Blanka Tóth3, Ivan Marchionni1, Christopher M Henstridge2, Barna Dudok4, Kata Kenesei2, László Barna2, Szilárd I Szabó2, Tibor Renkecz3, Michelle Oberoi1, Masahiko Watanabe5, Charles L Limoli6, George Horvai7, Ivan Soltesz1, István Katona8.   

Abstract

Persistent CB1 cannabinoid receptor activity limits neurotransmitter release at various synapses throughout the brain. However, it is not fully understood how constitutively active CB1 receptors, tonic endocannabinoid signaling, and its regulation by multiple serine hydrolases contribute to the synapse-specific calibration of neurotransmitter release probability. To address this question at perisomatic and dendritic GABAergic synapses in the mouse hippocampus, we used a combination of paired whole-cell patch-clamp recording, liquid chromatography/tandem mass spectrometry, stochastic optical reconstruction microscopy super-resolution imaging, and immunogold electron microscopy. Unexpectedly, application of the CB1 antagonist and inverse agonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide], but not the neutral antagonist NESS0327 [8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-5,6-dihydro-4H-benzo[2,3]cyclohepta[2,4-b]pyrazole-3-carboxamine], significantly increased synaptic transmission between CB1-positive perisomatic interneurons and CA1 pyramidal neurons. JZL184 (4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate), a selective inhibitor of monoacylglycerol lipase (MGL), the presynaptic degrading enzyme of the endocannabinoid 2-arachidonoylglycerol (2-AG), elicited a robust increase in 2-AG levels and concomitantly decreased GABAergic transmission. In contrast, inhibition of fatty acid amide hydrolase (FAAH) by PF3845 (N-pyridin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide) elevated endocannabinoid/endovanilloid anandamide levels but did not change GABAergic synaptic activity. However, FAAH inhibitors attenuated tonic 2-AG increase and also decreased its synaptic effects. This antagonistic interaction required the activation of the transient receptor potential vanilloid receptor TRPV1, which was concentrated on postsynaptic intracellular membrane cisternae at perisomatic GABAergic symmetrical synapses. Interestingly, neither AM251, JZL184, nor PF3845 affected CB1-positive dendritic interneuron synapses. Together, these findings are consistent with the possibility that constitutively active CB1 receptors substantially influence perisomatic GABA release probability and indicate that the synaptic effects of tonic 2-AG release are tightly controlled by presynaptic MGL activity and also by postsynaptic endovanilloid signaling and FAAH activity. SIGNIFICANCE STATEMENT: Tonic cannabinoid signaling plays a critical role in the regulation of synaptic transmission. However, the mechanistic details of how persistent CB1 cannabinoid receptor activity inhibits neurotransmitter release have remained elusive. Therefore, electrophysiological recordings, lipid measurements, and super-resolution imaging were combined to elucidate those signaling molecules and mechanisms that underlie tonic cannabinoid signaling. The findings indicate that constitutive CB1 activity has pivotal function in the tonic control of hippocampal GABA release. Moreover, the endocannabinoid 2-arachidonoylglycerol (2-AG) is continuously generated postsynaptically, but its synaptic effect is regulated strictly by presynaptic monoacylglycerol lipase activity. Finally, anandamide signaling antagonizes tonic 2-AG signaling via activation of postsynaptic transient receptor potential vanilloid TRPV1 receptors. This unexpected mechanistic diversity may be necessary to fine-tune GABA release probability under various physiological and pathophysiological conditions.
Copyright © 2015 Lee et al.

Entities:  

Keywords:  2-arachidonoylglycerol; GABA; TRPV1; endocannabinod; hippocampus; interneuron

Mesh:

Substances:

Year:  2015        PMID: 26157003      PMCID: PMC4495235          DOI: 10.1523/JNEUROSCI.4112-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  114 in total

1.  Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.

Authors:  Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

Review 2.  Principles: receptor theory in pharmacology.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

3.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

Review 4.  Presynaptic modulation by endocannabinoids.

Authors:  David M Lovinger
Journal:  Handb Exp Pharmacol       Date:  2008

5.  Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.

Authors:  Anikó Ludányi; Loránd Eross; Sándor Czirják; János Vajda; Péter Halász; Masahiko Watanabe; Miklós Palkovits; Zsófia Maglóczky; Tamás F Freund; István Katona
Journal:  J Neurosci       Date:  2008-03-19       Impact factor: 6.167

Review 6.  Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations.

Authors:  Thomas Klausberger; Peter Somogyi
Journal:  Science       Date:  2008-07-04       Impact factor: 47.728

Review 7.  Chemical probes of endocannabinoid metabolism.

Authors:  Jacqueline L Blankman; Benjamin F Cravatt
Journal:  Pharmacol Rev       Date:  2013-03-19       Impact factor: 25.468

8.  Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation.

Authors:  Tricia H Smith; Lawrence C Blume; Alex Straiker; Jordan O Cox; Bethany G David; Julie R Secor McVoy; Katherine W Sayers; Justin L Poklis; Rehab A Abdullah; Michaela Egertová; Ching-Kang Chen; Ken Mackie; Maurice R Elphick; Allyn C Howlett; Dana E Selley
Journal:  Mol Pharmacol       Date:  2015-02-05       Impact factor: 4.436

9.  CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.

Authors:  Jason L Niehaus; Yunguang Liu; Kathleen T Wallis; Michaela Egertová; Sheela G Bhartur; Somnath Mukhopadhyay; Shanping Shi; Hengjun He; Dana E Selley; Allyn C Howlett; Maurice R Elphick; Deborah L Lewis
Journal:  Mol Pharmacol       Date:  2007-09-25       Impact factor: 4.436

10.  Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling.

Authors:  Barna Dudok; László Barna; Marco Ledri; Szilárd I Szabó; Eszter Szabadits; Balázs Pintér; Stephen G Woodhams; Christopher M Henstridge; Gyula Y Balla; Rita Nyilas; Csaba Varga; Sang-Hun Lee; Máté Matolcsi; Judit Cervenak; Imre Kacskovics; Masahiko Watanabe; Claudia Sagheddu; Miriam Melis; Marco Pistis; Ivan Soltesz; István Katona
Journal:  Nat Neurosci       Date:  2014-12-08       Impact factor: 24.884

View more
  58 in total

1.  Correlated confocal and super-resolution imaging by VividSTORM.

Authors:  László Barna; Barna Dudok; Vivien Miczán; András Horváth; Zsófia I László; István Katona
Journal:  Nat Protoc       Date:  2015-12-30       Impact factor: 13.491

Review 2.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

3.  Anandamide Signaling Augmentation Rescues Amygdala Synaptic Function and Comorbid Emotional Alterations in a Model of Epilepsy.

Authors:  Roberto Colangeli; Maria Morena; Quentin J Pittman; Matthew N Hill; G Campbell Teskey
Journal:  J Neurosci       Date:  2020-06-29       Impact factor: 6.167

4.  Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein.

Authors:  Changqing Xu; Douglas J Hermes; Blessing Nwanguma; Ian R Jacobs; Kenneth Mackie; Somnath Mukhopadhyay; Aron H Lichtman; Bogna Ignatowska-Jankowska; Sylvia Fitting
Journal:  Mol Cell Neurosci       Date:  2017-07-19       Impact factor: 4.314

5.  A Feedforward Inhibitory Circuit Mediated by CB1-Expressing Fast-Spiking Interneurons in the Nucleus Accumbens.

Authors:  William J Wright; Oliver M Schlüter; Yan Dong
Journal:  Neuropsychopharmacology       Date:  2016-12-08       Impact factor: 7.853

Review 6.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

7.  A role for corticotropin-releasing factor signaling in the lateral habenula and its modulation by early-life stress.

Authors:  Michael E Authement; Ludovic D Langlois; Ryan D Shepard; Caroline A Browne; Irwin Lucki; Haifa Kassis; Fereshteh S Nugent
Journal:  Sci Signal       Date:  2018-03-06       Impact factor: 8.192

Review 8.  Hippocampal GABAergic Inhibitory Interneurons.

Authors:  Kenneth A Pelkey; Ramesh Chittajallu; Michael T Craig; Ludovic Tricoire; Jason C Wester; Chris J McBain
Journal:  Physiol Rev       Date:  2017-10-01       Impact factor: 37.312

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

10.  Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin.

Authors:  Bárbara S Pinheiro; Cristina Lemos; Fernanda Neutzling Kaufmann; Joana M Marques; Carla S da Silva-Santos; Eugénia Carvalho; Ken Mackie; Ricardo J Rodrigues; Rodrigo A Cunha; Attila Köfalvi
Journal:  Brain Res Bull       Date:  2016-05-18       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.